Santina Cutrupi

Dr. Santina Cutrupi

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2002 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
Gianluca BaldanziGianluca Baldanzi
Gianluca Baldanzi
Nicoletta FilighedduNicoletta Filigheddu
Nicoletta Filigheddu
SCSantina Cutrupi
Santina Cutrupi
FCFilomena Catapano
Filomena Catapano
SBSara Bonissoni
Sara Bonissoni
AGAndrea Graziani
Andrea Graziani
Ghrelin is an acyl-peptide gastric hormone acting on the pituitary and hypothalamus to stimulate growth hormone (GH) release, adiposity, and appetite. Ghrelin endocrine activities are entirely dependent on its acylation and are mediated by GH secretagogue (GHS) receptor (GHSR)-1a, a G protein–coupled receptor mostly expressed in the pituitary and hypothalamus, previously identified as the receptor for a group of synthetic molecules featuring GH secretagogue (GHS) activity. Des-acyl ghrelin, which is far more abundant than ghrelin, does not bind GHSR-1a, is devoid of any endocrine activity, and its function is currently unknown. Ghrelin, which is expressed in heart, albeit at a much lower level than in the stomach, also exerts a cardio protective effect through an unknown mechanism, independent of GH release. Here we show that both ghrelin and des-acyl ghrelin inhibit apoptosis of primary adult and H9c2 cardiomyocytes and endothelial cells in vitro through activation of extracellular signal–regulated kinase-1/2 and Akt serine kinases. In addition, ghrelin and des-acyl ghrelin recognize common high affinity binding sites on H9c2 cardiomyocytes, which do not express GHSR-1a. Finally, both MK-0677 and hexarelin, a nonpeptidyl and a peptidyl synthetic GHS, respectively, recognize the common ghrelin and des-acyl ghrelin binding sites, inhibit cell death, and activate MAPK and Akt. These findings provide the first evidence that, independent of its acylation, ghrelin gene product may act as a survival factor directly on the cardiovascular system through binding to a novel, yet to be identified receptor, which is distinct from GHSR-1a.

1 March 2007 in Molecular Biology of the Cell
Verified
Journal Article
Closed access
Nicoletta FilighedduNicoletta Filigheddu
Nicoletta Filigheddu
VGViola F. Gnocchi
Viola F. Gnocchi
MCMarco Coscia
Marco Coscia
MCMiriam Cappelli
Miriam Cappelli
Paolo PorporatoPaolo Porporato
Paolo Porporato
AGAndrea Graziani
Andrea Graziani
Ghrelin is an acylated peptidyl gastric hormone acting on the pituitary and hypothalamus to stimulate appetite, adiposity, and growth hormone release, through activation of growth hormone secretagogue receptor (GHSR)-1a receptor. Moreover, ghrelin features several activities such as inhibition of apoptosis, regulation of differentiation, and stimulation or inhibition of proliferation of several cell types. Ghrelin acylation is absolutely required for both GHSR-1a binding and its central endocrine activities. However, the unacylated ghrelin form, des-acyl ghrelin, which does not bind GHSR-1a and is devoid of any endocrine activity, is far more abundant than ghrelin in plasma, and it shares with ghrelin some of its cellular activities. Inhere we show that both ghrelin and des-acyl ghrelin stimulate proliferating C2C12 skeletal myoblasts to differentiate and to fuse into multinucleated myotubes in vitro through activation of p38. Consistently, both ghrelin and des-acyl ghrelin inhibit C2C12 proliferation in growth medium. Moreover, the ectopic expression of ghrelin in C2C12 enhances differentiation and fusion of these myoblasts in differentiation medium. Finally, we show that C2C12 cells do not express GHSR-1a, but they do contain a common high-affinity binding site recognized by both acylated and des-acylated ghrelin, suggesting that the described activities on C2C12 are likely mediated by this novel, yet unidentified receptor for both ghrelin forms.

17 March 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
LCLivia Caizzi
Livia Caizzi
Giulio FerreroGiulio Ferrero
Giulio Ferrero
SCSantina Cutrupi
Santina Cutrupi
FCFRANCESCA CORDERO
FRANCESCA CORDERO
CBCecilia Ballaré
Cecilia Ballaré
MBMichele De Bortoli
Michele De Bortoli
Significance: Estrogen receptor-α (ERα) is a key protein in breast cancer and treatments targeting ERα are among the most widely used and effective in clinics. Although the role of estrogen-stimulated ERα in breast cancer has been exhaustively described, the functions of ERα in the absence of estrogen is hill-defined. In this work, we show that ERα binds extensively to the genome of breast cancer cells in the absence of estrogen, where it regulates the expression of hundreds of genes endowed with developmental functions. Our data suggest that ERα has a fundamental role in the homeostasis of luminal epithelial cells also when estrogen is ablated physiologically or pharmacologically.

1 September 2000 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
SCSantina Cutrupi
Santina Cutrupi
Gianluca BaldanziGianluca Baldanzi
Gianluca Baldanzi
DGDaniela Gramaglia
Daniela Gramaglia
AMAntonella Maffè
Antonella Maffè
DSDick Schaap
Dick Schaap
AGAndrea Graziani
Andrea Graziani
Diacylglycerol kinases are involved in cell signaling, either as regulators of diacylglycerol levels or as intracellular signal‐generating enzymes. However, neither their role in signal transduction nor their biochemical regulation has been elucidated. Hepatocyte growth factor (HGF), upon binding to its tyrosine kinase receptor, activates multiple signaling pathways stimulating cell motility, scattering, proliferation and branching morphogenesis. Herein we demonstrate that: (i) the enzymatic activity of α‐diacylglycerol kinase (αDgk) is stimulated by HGF in epithelial, endothelial and αDgk‐transfected COS cells; (ii) cellular expression of an αDgk kinase‐defective mutant inhibits activation of endogenous αDgk acting as dominant negative; (iii) specific inhibition of αDgk prevents HGF‐induced cell movement of endothelial cells; (iv) HGF induces the association of αDgk in a complex with Src, whose tyrosine kinase activity is required for αDgk activation by HGF; (v) Src wild type stimulates αDgk activity in vitro ; and (vi) αDgk can be tyrosine phosphorylated in intact cells.

3 May 2004 in Oncogene
Verified
Journal Article
Closed access
Gianluca BaldanziGianluca Baldanzi
Gianluca Baldanzi
SMStefania Mitola
Stefania Mitola
SCSantina Cutrupi
Santina Cutrupi
Nicoletta FilighedduNicoletta Filigheddu
Nicoletta Filigheddu
WBWim J van Blitterswijk
Wim J van Blitterswijk
AGAndrea Graziani
Andrea Graziani

13 November 2017 in OncoImmunology
Verified
Journal Article
Open access
SBSimone Borgoni
Simone Borgoni
AIAndrea Iannello
Andrea Iannello
SCSantina Cutrupi
Santina Cutrupi
PAPaola Allavena
Paola Allavena
Maurizio D'IncalciMaurizio D'Incalci
Maurizio D'Incalci
Paola CappelloPaola Cappello
Paola Cappello
Pancreatic Ductal Adenocarcinoma (PDA) is characterized by a complex tumor microenvironment that supports its progression, aggressiveness and resistance to therapies. The delicate interplay between cancer and immune cells creates the conditions for PDA development, particularly due to the functional suppression of T cell anti-tumor effector activity. However, some of the mechanisms involved in this process are still poorly understood. In this study, we analyze whether the functional and epigenetic profile of T cells that infiltrate PDA is modulated by the microenvironment, and in particular by tumor-associated macrophages (TAMs). CD4 and CD8 T cells obtained from mice orthotopically injected with syngeneic PDA cells, and untreated or treated with Trabectedin, a cytotoxic drug that specifically targets TAMs, were sorted and analyzed by flow cytometry and characterized for their epigenetic profile. Assessment of cytokine production and the epigenetic profile of genes coding for IL10, T-bet and PD1 revealed that T cells that infiltrated PDA displayed activated Il10 promoter and repressed T-bet activity, in agreement with their regulatory phenotype (IL10high/IFNγlow, PD1high). By contrast, in Trabectedin-treated mice, PDA-infiltrating T cells displayed repressed Il10 and Pdcd1 and activated T-bet promoter activity, in accordance with their anti-tumor effector phenotype (IL10low/IFNγhigh), indicating a key role of TAMs in orchestrating functions of PDA-infiltrating T cells by modulating their epigenetic profile towards a pro-tumoral phenotype. These results suggest the targeting of TAMs as an efficient strategy to obtain an appropriate T cell anti-tumor immune response and open new potential combinations for PDA treatment.